Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome
نویسندگان
چکیده
منابع مشابه
Purtscher-Like Retinopathy Associated with Atypical Hemolytic Uremic Syndrome
A 25-year-old woman presented with acute bilateral blurred vision and history of headache, dizziness, and syncope for three days. Her visual acuity was 20/60 in both eyes. Fundoscopy revealed multiple bilateral peripapillary yellow-white patches like cotton wool spots, intraretinal hemorrhages and macular edema. The patient was diagnosed with Purtscher-like retinopathy based on the retinal find...
متن کاملEculizumab in atypical hemolytic-uremic syndrome.
n engl j med 369;14 nejm.org october 3, 2013 1377 [CI], 0.57 to 0.83) for the first 21 days, 1.00 (95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 (95% CI, 0.18 to 0.82) for 61 to 90 days. We also await results of trials such as POINT and TARDIS for confirmation of these results in non-Chinese populations. We agree with Jeong that there may be important differences according to the patients’ ...
متن کاملEculizumab for atypical hemolytic-uremic syndrome.
n engl j med 360;5 nejm.org january 29, 2009 542 myocardial infarction or coronary death, a 24% decrease in the need for coronary bypass surgery, and a 17% decrease in the rate of fatal or nonfatal stroke.2 The recently reported results of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin (20 mg per day) show th...
متن کاملProphylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
To the Editor: Atypical hemolytic–uremic syndrome is a rare microangiopathic hemolytic condition characterized by thrombocytopenia and acute renal failure.1 The prognosis for patients with atypical hemolytic–uremic syndrome with a factor H mutation is poor; 60% have end-stage renal disease or die within a year.2 The expected rate of graft failure due to recurrent atypical hemolytic–uremic syndr...
متن کاملCritical appraisal of eculizumab for atypical hemolytic uremic syndrome.
The biology of atypical hemolytic uremic syndrome has been shown to involve inability to limit activation of the alternative complement pathway, with subsequent damage to systemic endothelial beds and the vasculature, resulting in the prototypic findings of a thrombotic microangiopathy. Central to this process is the formation of the terminal membrane attack complex C5b-9. Recently, application...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Ophthalmology
سال: 2017
ISSN: 0165-5701,1573-2630
DOI: 10.1007/s10792-017-0470-1